growth/diversif stori continu unfold price
remain buyer share level approach humira
out-performance key theme sever quarter long promis
diversif stori come increas focu play along
expect continu humira out-performance well signific leverag
still compel valuat continu recommend purchas share
commerci engin fire cylind morn post strong
ep versu consensu rais guidanc revenu
consensu ep previou guidanc month ago
consensu out-performance consist thesi
humira continu market domin revenu versu consensu
augment strength across rest busi
 leverag full display tax reform contribut guidanc
rang manag point y/i ep growth oper driven
long-term tax rate gradual increas also like
provid investor signific comfort
meanwhil long promis pipelin pois deliv come quarter
shortag valid pipelin catalyst come quarter includ approv
decis elagolix endometriosi venclexta r/r cll registr rova-
sclc triniti data regulatori file risankizumab psoriasi
addit upadacitinib ra data follow file
roll new model today rais estim concurr today print
roll new detail model complet product build
also rais ep estim
despit run remain valu stock view includ today move
plug midpoint new guidanc trade ep
compar group yet factor growth note abbv
pe/g discount group mean given think share
addit room run remain buyer level approach
trial failur key drug deterior price outlook unexpect patent loss
brand pharmaceut compani key product span inflammatori
diseas oncolog virolog well specialist area
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
new model includ detail revenu build largest product incorpor
updat guidanc well long-term guidanc previous
issu compani product sale summari includ note
addit consist valuat methodolog large-cap biotech
compani use discount price-to-earnings approach deriv one year price target
appli multipl ep estim discount back
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
provis incom tax tax benefit
page
dollar except per share data
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit share
page
